Critics Say New At-Home Test Is Expensive and Late to Market

They say the first over-the-counter test for COVID-19 to get EUA status from the FDA “is a waste of money”

ONCE AGAIN, THE COMBINATION of the pandemic and the federal government may be creating a credible new competitor in the in vitro diagnostics (IVD) industry. This time, the lucky company is Ellume, which was just awarded $231.8 million from the Biden administration to scale up production of a home test for SARS-CoV-2. Ellume was given an emergency-use authorization (EUA) from the federal Food and …

Critics Say New At-Home Test Is Expensive and Late to Market Read More »

To access this post, you must purchase The Dark Report.

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: customerservice@darkintelligencegroup.com

Critics Say New At-Home Test Is Expensive and Late to Market

They say the first over-the-counter test for COVID-19 to get EUA status from the FDA “is a waste of money”

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month